Delivery Order SPE2DB22D3401-SPE2DB25FT5CW
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,931.30 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ondansetron HCl 4 mg tablets (500 count). The contract, which is of the firm fixed-price delivery order type with no set-aside designation, represents a competitive award to the pharmaceutical distributor. Performance of this order is scheduled for completion by July 15, 2025, and will be executed at the awardee's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a $11,073.06 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,962.99 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement with no set-aside designation. The place of performance is listed as Conshohocken, Pennsylvania, which is also the location of AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 500 units, with a ceiling value of $5,252.73. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30 units. This contract, valued at $1,197.33, represents a firm fixed price delivery order with an ultimate completion date of August 28, 2025. The order will be fulfilled from AmerisourceBergen's facilities in Conshohocken, Pennsylvania. No set-aside designation was applied to this award, indicating it was competitively procured...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 count) valued at $6,599.70. This is a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 tablets) with a ceiling value of $5,367.10. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,101.46 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets in unit dose packages of 100 units. The contract represents a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and was awarded on August 8, 2025. This award carries no set-aside designation and was competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $18,664.07 delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 4 mg tablets (30-count units) with a completion date of September 11, 2025. This competitive award, issued as a firm fixed-price delivery order with no set-aside designation, represents a single transaction under AmerisourceBergen's larger contract vehicle with the agency. The pharmaceutical product will be delivered to the company's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30 units. This order, valued at $14,531.95, represents a competitive firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT5CWDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,922.80 to AmerisourceBergen Drug Corp for Ondansetron HCL 4 mg tablets (30-count units) on July 14, 2025, with an ultimate completion date of July 15, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. Ondansetron, an antiemetic medication commonly used for nausea and vomiting prevention, represents a routine pharmaceutical commodity within the DLA's medical supply chain serving the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 7/14/25 |